Activity Report
Activity Report 2022
Scientific Programmes
Research lines
Cancer
Infectious diseases
Rare diseases
The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry and Biomedicine, with emphasis on Structural, Molecular and Cell Biology. An integrative Bioinformatics Program extrapolates relevant conclusions from basic science.
- Personalized medicine
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Liver Diseases
- Rare Diseases
- Biomarkers for Diagnosis
- Biomarkers for Prognosis
- Drug Design and Discovery
Molecular Recognition and Host-Pathogen
- Rare Diseases
- Homeostasis
- Viral Infections
- Bacterial Infections
- Prion Disease
- Tick-Borne Disease
- Immune Response
- Drug Design and Discovery
Platforms
- NMR Spectroscopy
- Macromolecular Crystallography
- Electron Microscopy
- Genome Analysis
- Proteomics
- Metabolomics
- Animal Facility
Generation of
knowledge
Technology
transfer
Commercialization of
results
Scientific Programmes
Metabolism & Cell Signaling in Disease
Brain
Breast
Colon
Liver
Prostate
- Target discovery and evaluation of their therapeutic potential
- Cancer and more: Identification of biomarkers with potential diagnostic value
- Novel therapies against rare diseases
- The molecular basis of fibrosis
- Nonalcoholic steatohepatitis
The Research Programmes
Molecular Recognition & Host-Pathogen Interactions
Parasites
Vaccines
Antibiotics
Membrane remodelling
Animal and plant viruses
- Bacterial and Viral Infections: Vaccines for human and animal health
- Mechanisms of membrane remodelling during microbial invasion and propagation
- Plant vaccines and transgenics
- Antibiotics research and molecular characterization
The Research Programmes
Technology Platforms
Genome Analysis Platform
Proteomics Platform
Metabolomics Platform
Animal Facility
Antibodies Production
Drug Repositioning & Discovery
Nuclear Magnetic Resonance
Macromolecular Crystallography
Electron Microscopy Platform
Collaboration Models
Services
R&D Collaborations
Consulting
About Us
Mission:
Conducting research of excellence in the field of the life sciences, covering the entire value of R&D&i, including technology transfer and commercial exploitation of the generated scientific results.
Strategic Challenges:
- Research of excellence
- Technology Transfer
- Collaboration with RVCTI agents
- International recognition
- Training and promotion of research talent
- Attraction and retention of talent
- Communication and Outreach
- Excellence in Management
Strategy:
Commitment to specialization and excellence
Competitiveness:
- Leading infrastructures
- Human Resources
- Technical and administrative support
- Competitive salaries
- Goal-Fulfillment Incentives
Personnel
Personnel 2022.12.31: 0
FTE (2022): 0
Permanent (FTE): 0 (46.3%)
Gender Distribution
-
0% Female
127 -
0% Male
94 -
LISMI - Law of Social Integration of the Handicapped
4
221 Total CIC bioGUNE Personnel
-
0% Research
183 -
0% Administration and Services
38
Researchers Distribution by Professional Category
| nº | % |  |
 |
||
| Researchers | 133 | 73 | 71 | 62 | |
| • Principal investigators/Platform Managers | 20 | 11 | 7 | 13 | |
| • Postdoctoral Researchers/Research Assistant/Specialist | 51 | 28 | 31 | 20 | |
| • PhD Candidates | 62 | 34 | 33 | 29 | |
| Technicians | 50 | 27 | 37 | 13 |
Research Distribution by Geographic Origin
Research Distribution by Geographic Origin
-
0% Spain
182 researchers -
0% Rest of Europe
23 researchers -
0% America
14 researchers -
0% Asia
2 researchers
Funding
Total 2022 R&D Budget: 0 million €
Running R&D Projects: 0
New R&D Projects: 0
- 0 % Competitive Public Funding
- 0 % Core Funding
-
0
% Basque Government Departments
11.938 k€ -
0
% R&D Contracts, Research Services & Others
7.674 k€ -
0
% MINECO & MEDC (Government of Spain)
3.030 k€ -
0 % EU & International Projects
1.888 k€
Technology Transfer
Economic Activity: 6.574.569€
- Basque Country: 0%
- National: 0%
- International: 0%
New Research Contracts 0
0 New Patent Families (4 EPO, 1 USTPO)
0 Active Patents
0 Technology Transfer Agreements
0 Spin-Off
Active Patents
Personnel
Social Commitment
Talent opportunity
NEW CALL Closing october 2022
CIC bioGUNE Initiative
Fellowships Fundación ONCE - CIC bioGUNE New Applications Awarded
- Predoctoral Trainee
- Postdoctoral Trainee
Funding Applications
140 Applications
Basque Country
0%
18 Applications
- 0 Research Projects
- 0 Human Resources
- 0 Research stage
- 0 Infrastructure (equipment)
Spain
0%
70 Applications
- 0 Research Projects
- 0 Human Resources
- 0 Research Networks
- 0 Research Awards
- 0 Strategic Projects
- 0 Research Stage
Europe 0%
International 0%
43 European Applications
- 0 Research Projects
- 0 Human Resources
- 0 Research Networks
- 0 Research Stages
9 International Applications
- 0 Research Projects
49 New Applications Awarded
Basque Country
0%
6 Applications
- 0 Research Projects
- 0 Human Resources
- 0 Equipment
Spain
0%
32 Applications
- 0 Research Projects
- 0 Human Resources
- 0 Research Awards
- 0 Strategic Projects
- 0 Research Stage
Europe 0%
International 0%
9 European Applications
- 0 Research Projects
- 0 Research Stage
2 International Applications
- 0 Research Projects
Competitive Funding
Key Action
Elkartek 2022: A. Palazón & M. Vivanco, with many others
Desarrollo de métodos diagnósticos y nuevas terapias en la era de la medicina de precisión en cáncer
Developing new diagnostic methods and novel therapies for precision medicine in cancer
 |
 |
 |
 |
 |
 |
 |
 |
ELKARTEK 2022
Coordinator: CIC bioGUNE
- Small Molecules
- Cell Therapy
- Glycomimetics
- RNA Therapy
- Biologics
Coordinators: AsÃs Palazón & MarÃa Vivanco
Competitive Funding
Human Resources
Key Successful Applications
Spain
Juan de la Cierva
Program
Investigator:
MarÃa Elena Laugieri
Supervisor:
Jesús Jiménez-Barbero
Ramón y Cajal
Program
Investigator:
Gabriel Ortega
Precision Medicine &
Metabolism Lab
Sello de Excelencia ISCIII-HEALTH
Investigator:
Antonela S. Stagnoli
Supervisor:
Nicola GA Abrescia
Investigator:
Agustina Creus
Supervisor:
Malu MartÃnez-Chantar
Euskadi
Investigator:
Luca Unione
Chemical Glycobiology Lab
Investigator:
Oihana Iriondo Martinez de Zuazo
Cancer Cell Signaling & Metabolism Lab
Private
Investigator
Investigator:
Amaia Zabala
Director: Arkaitz Carracedo
AECC Predoctoral
– JP Bizkaia
Investigator:
Naiara Gutiez
Supervisor: Juan Anguita
Competitive Funding
Europe
Nicola GA Abescia
Coordinator:
HORIZON-CL6-2021-FARM2FORK-01
SPIDVAC - Improved control of priority animal diseases: Novel vaccines and companion diagnostic tests for African horse sickness, peste des petits ruminants and foot-and-mouth disease
Óscar Millet
Coordinator:
HORIZON-CL6-2022-FARM2FORK-01
CoDiet - Combatting diet related non-communicable disease through enhanced surveillance
Óscar Millet
Coordinator:
HORIZON-INFRA-2021-DEV-01
R-NMR - Remote NMR (R-NMR): Moving NMR infrastructures to remote access capabilities
Jesús Jiménez-Barbero
Coordinator:
HORIZON-WIDERA-2021-ACCESS-03
GlycoTwinning - Building Networks to Excel in Glycosciences
Juan Manuel Falcón
Coordinator:
HORIZON-WIDERA-2021-ACCESS-03
EVCA - Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles
Juan Manuel Falcón
Coordinator:
HORIZON-HLTH-2022-STAYHLTH-02-01
Halt-RONIN -Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies
0 M€ CIC bioGUNE
Spain
Proyectos Generación de Conocimiento
Funded projects: 0
Total Grant Amount (3 years): 0 M€
Doctoral Candidates: 0 FPI
Gonzalo Jiménez-Osés, Jesús Jiménez-Barbero, JoaquÃn Castilla, Juan Anguita, Juan Manuel Falcón, Mikel Valle, Nicola GA Abrescia, Óscar Millet
AsÃs Palazón
Proyectos Estratégicos orientados a la transición ecológica y digital
Desarrollo de una plataforma analÃtica sostenible para la salud digital de la era post-pandémica
Private Funding
Creutzfeldt-Jakob Disease Foundation
JoaquÃn Castilla
Grant Applications
Development and characterization of the fastest animal model able to propagate GSS prions faithfully
Alberto Fernández-Tejada
AECC Lab
Development of a cancer vaccine platform based on synthetic saponin adjuvants and tumor peptide antigens
Institut Germans Trias i Pujol
Malu MartÃnez-Chantar
AECC Coordinados
Precision medicine for hepatoblastoma: identification of novel therapies and predictive biomarkers using a unique EU biorepository
Juan Manuel Falcón
Research Grant to Promote Diversity
Exosomes in Alzheimer's Disease from a metabolic point of view
Technology Transfer Projects
Euskadi
Malu Martínez-Chantar
siRNA-GalNAC for Liver Disease
Óscar Millet
Metabolic Age Product
Competitive Funding
Technology Transfer Projects
Spain
Pruebas de Concepto, I+D+i
AsÃs Palazón
Óscar Millet
Jesús Jiménez-Barbero
Gonzalo Jiménez-Osés
Coordinator
Óscar Millet
Colaboración Público-Privada
Desarrollo de una formulación oral de ciclopirox para el tratamiento de la porfiria eritropoyética congénita
Europe
AsÃs Palazón
ERC Proof of Concept
FIH-IO - Development of a first-in-class inhibitor of FIH for cancer immunotherapy
Alberto Fernández Tejada
ERC Proof of Concept
ADJUVACCINE - Development of a marketable adjuvant candidate for vaccine applications
Spain:
Complementary Plans
Click to view in PDF
Subvenciones directas a las comunidades autónomas para financiar la incorporación a programas de los Planes Complementarios de I+D+I que forman pare del componente 17 del Plan de Recuperación, Transformación y Resiliencia, denominado "Reforma Institucional y fortalecimiento de las capacidades del Sistema Nacional de Ciencia, TecnologÃa e Innovación".
Competitive Funding
Severo Ochoa 2021
Awarded in 2022
0 M€
10 new contracts for PhD candidates
Click to view in PDF
Accreditations
Quality System Management
Newborns urine sample screening for the detection of inborn errors of metabolism.
2nd follow up audit
Provision of quality control service of samples by electron microscopy.
Acreditation audit Tentative date First half 2023
Design, development & manufacture of software to aid in the diagnosis of newborn congenital metabolic errors
2st follow up audit
Prior Operating License (in the process of submitting an application)
Design and development of R+D projects to discover new drugs nd biomarkers for diagnosis and prognosis.
Re-accreditation audit & update to 2021 version
UNE166002 R&D Management
Click on the image to see it enlarged in pdf
Transition to UNE166002:2021
Euskadi: Industrial Competitiveness
& Sustainability Projects
Commitment of the 22 participants
17 companies 5 hospitals 2 sectorial cluster/associations 3 scientific-technological entities
Contribute their skills:
Research, technological development, industrial design, manufacturing, certification, intellectual protection and technological surveillance
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Solución integral de diagnóstico y terapias para la gestión de la COVID-19 y futuras pandemias
Training: COMPLIANCE
What does compliance mean?
- Risk management system and internal control
Who is this training for?
- On-site training for all members of CIC bioGUNE
Which will be the main contents?
- Criminal liability of CIC bioGUNE as a legal person
- Implemented system in CIC bioGUNE: risk assessment, politics, procedures, Ethics Channel, dissemination on the corporate website
Which are the essential elements of the compliance system I should be aware of?
- Code of Ethics and Conduct
- Protocol for action against Conflicts of Interest
- Ethics Channel
Which are some of the main risks in the performance of scientific activity?
- Unethical behaviour
- Situations of gender inequality
- Scientific Conflict of Interest
- Management of public funds by Principal Investigators
- Gifts, incentives, special attention or privileges
Activities
Equality Plan
TÃtulo: Torres Gemelas
Autora: Coralia Peréz
TÃtulo: Planeta 290520L
Autora: Laura Bozal
PLANETA 290520L
DÃa0-9:00h: Aterrizaje planeta 29052020L-TIERRA. Viajo en forma acorporal. Decido adoptar una apariencia análoga a los autóctonos. Consulto el Catálogo de formas terrestres-CFT. Existen dos complexiones a elegir: los que no extirpan voluntariamente sus pelos y, sin ser necesariamente más inteligentes, reciben más objetos de papel/metal denominados dinero por su trabajo; y las que expulsan un lÃquido rojo una semana al mes u otro ser humano chiquitÃn con dolor y son peor remuneradas, aunque ejecuten las mismas funciones.
Sin duda, decido personarme en los primeros, denominados hombres. Y me pregunto, ¿quién querrÃa pertenecer a las segundas en este planeta tan extraño?
Click on the image to see enlarged in pdf
Reto 25N
Acoso Sexual vs Acoso por razón de sexo
¿Sabes identificarlos?
Scientific Outreach
Bulletin
Click on the images to see them enlarged in pdf
Scientific Annual Review
Click on the image to see it enlarged in pdf
NEBTs
2016. Discovery of innovative "first-in-class" therapies, based on the principle of pharmacological chaperones, for the treatment of rare and ultra-rare diseases. 1 ODD (EMA & FDA) entering in Phase I-IIa in USA.
2020. Innovation & development: exploitation of technologies for processing and analysis of biological, biochemical, biotechnological & medical data.
2022
Focused on the development of cellular immunotherapies for the treatment of solid tumors.
Collaboration
Tech Boost Progam, CIC bioGUNE
AsÃs Palazón
Master Final Degree
Entrepreneurship in Biotech
Business Plan, Opportunity Analysis in CAR-T
Research, Development & Innovation in biomedical technology
Renewal of Collaboration Agreement, March 2022
Awards and Recognitions
National Award for Young Investigators in Biology "Margarita Salas"
Óscar Millet
German-Spain Award in Chemistry
Hermanos Elhúyar - Goldschmidt
Arkaitz Carracedo
Research Award
Fundación Jesús Serra
Key Facts
CIC bioGUNE receives again the Severo Ochoa Center of Excellence in 2022. The purpose of this distinction is to give visibility to research centers, in any scientific area, that demonstrate impact and scientific leadership at an international level and actively collaborate with their social and business environment.
Dr. Arkaitz Carracedo receives the National Margarita Salas Award for Young Scientists in the field of Biology.
The AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) accreditation for CIC bioGUNE is renewed and the accreditations of the UNE 166002:2021, ISO 9011:2015 and ISO 13485:2016 standards are maintained.
Agreements and Contracts: The Collaboration Agreement between CIC bioGUNE and the Tekniker Foundation has been renewed for carrying out joint projects on Research, Development and Innovation in biomedical technology.
On April 8, 2022 Bruker Española, S.A. and CIC bioGUNE signed a contract for the acquisition of a superconducting magnet for a NMR spectrometer with a magnetic field of 23.58 Teslas (1 GHz) to focus on Precision Medicine projects.
Osasunberri consortium, which gathers 23 Basque entities, has been created, funded by the Basque Government through the Program for the Promotion of Industrial Competitiveness & Sustainability. Its objective is the search for diagnostic solutions and therapies for the management of future pandemics.
Staff and HR: A new call for the Talent Opportunity Scholarship Program has been launched held, cofunded between the ONCE Foundation and CIC bioGUNE for the hiring of a postdoctoral fellow and a predoctoral fellow
Two new IKERBASQUE Research Fellows have joined the Chemical Glycobiology (Dr. Luca Unione) and Cancer Cell Signaling & Metabolism (Dr. Oihana Iriondo) laboratories.
Dr. Oscar Millet is recognized with the Elhuyar-Goldschmit Award from the German Chemical Society.
New technology-based companies (NEBT): On June 1, 2022, a new spin-off company, ZELULA BIOPHARMA, SL, has been created. Its corporate purpose is research, development, innovation, production, manufacturing, marketing, exploitation, distribution, import and/or export of pharmaceutical, biotechnological and health products, as well as the provision of associated services, with a strong focus on CAR-T therapies.
Diffusion: EUROMAR 2024 conference, the European Magnetic Resonance Meeting, will be hosted by CIC bioGUNE at Bilbao, under the presidency of Dr. Oscar Millet. EUROMAR is the main meeting in the field of NMR worldwide with representation of scientists from the five continents. It covers all aspects of NMR and MRI, including biomedical and clinical applications. The attendance of 1,000 scientists and the presentation of 400 posters are expected.
Funding:
The Ministry of Science and Innovation, through the State Program for Research, Development & Innovation Oriented to the Challenges of Society has granted CIC bioGUNE eight projects for a total amount of €1,966,250.
Moreover, CIC bioGUNE has obtained additional competitive funding through the following calls:
Ministry of Science and Innovation:
- Four "Proofs of Concept" projects.
- One "Ecological and Digital Transition" strategic project.
- One "Public-Private Partnership" project.
- Regarding personnel, Four Juan de Cierva and one Ramón y Cajal contracts.
Institute of Health Carlos III (ISCIII):
- Two "MSCA-ISCIII Health Seal of Excellence" projects
A Proposal on Precision Medicine from CIC bioGUNE has also been funded through the Complementary Plans for R+D+i in the field of Biotechnology applied to Health, within the Recovery, Transformation and Resilience Plan, dubbed "Institutional Reform and strengthening of the capacities of the National Science, Technology and Innovation System.
Research Activity
Regarding research activity, the key numbers for 2022 were:
Projects:
- 31 New research projects
- 104 Ongoing projects
Scientific production:
- 187 Publications, with 153 in Q1 and 66 in D1 Journals
- 9372 citations received
- 19 PhD Thesis were defended with 78 running PhD candidates
- 143 impacts in press, radio, and TV media
Intellectual property:
- 4 EPO, 3 PCT, and 5 Industrial Secrets
Publications
12
Average
Impact Factor
Highlights
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.
Fondevila MF, Fernandez U, Heras V, Parracho T, Gonzalez-Rellan MJ, Novoa E, Porteiro B, Alonso C, Mayo R, da Silva Lima N, Iglesias C, Filliol AA, Senra A, Delgado TC, Woodhoo A, Herrero L, Serra D, Prevot V, Schwaninger M, López M, Dieguez C, Millet O, Mato JM, Cubero FJ, Varela-Rey M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Schwabe RF, Nogueiras R.
J Hepatol. 2022 Jul;77(1):15-28. doi: 10.1016/j.jhep.2022.02.003. Epub 2022 Feb 12. PMID: 35167910.
Targeting NAE1-mediated protein hyper-NEDDylation halts holangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Olaizola P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, Cadamuro M, Azkargorta M, O'Rourke CJ, Caballero-Camino FJ, Olaizola I, Macias RIR, Marin JJG, Serrano-Maciá M, Martinez-Chantar ML, Avila MA, Aspichueta P, Calvisi DF, Evert M, Fabris L, Castro RE, Elortza F, Andersen JB, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM.
J Hepatol. 2022 Jul;77(1):177-190. doi: 10.1016/j.jhep.2022.02.007. Epub 2022 Feb 23. PMID: 35217064
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, Mercado-Gómez M, Gallet S, González-Rellan MJ, Fernandez U, Loyens A, Garcia-Vence M, Chantada-Vazquez MDP, Bravo SB, Marañon P, Senra A, Escudero A, Leiva M, Guallar D, Fidalgo M, Gomes P, Claret M, Sabio G, Varela-Rey M, Delgado TC, Montero-Vallejo R, Ampuero J, López M, Diéguez C, Herrero L, Serra D, Schwaninger M, Prevot V, Gallego-Duran R, Romero-Gomez M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Garcia-Monzon C, Gonzalez-Rodriguez A, Aspichueta P, Nogueiras R
J Hepatol. 2022 Jan;76(1):11-24. doi: 10.1016/j.jhep.2021.09.008. Epub 2021 Sep 21. PMID: 34555423.
Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure
Zhang IW, Curto A, López-Vicario C, Casulleras M, Duran-Güell M, Flores-Costa R, Colsch B, Aguilar F, Aransay AM, Lozano JJ, Hernández-Tejero M, Toapanta D, Fernández J, Arroyo V, Clà ria J
J Hepatol. 2022 Jan;76(1):93-106. doi: 10.1016/j.jhep.2021.08.009. Epub 2021 Aug 25. PMID: 34450236
Controlled masking and targeted release of redox-cycling ortho- quinones via a C-C bond-cleaving 1,6-elimination
Dunsmore L, Navo CD, Becher J, de Montes EG, Guerreiro A, Hoyt E, Brown L, Zelenay V, Mikutis S, Cooper J, Barbieri I, Lawrinowitz S, Siouve E, Martin E, Ruivo PR, Rodrigues T, da Cruz FP, Werz O, Vassiliou G, Ravn P, Jiménez-Osés G, Bernardes GJL
Nat Chem. 2022 Jul;14(7):754-765. doi: 10.1038/s41557-022-00964-7. Epub 2022 Jun 27. PMID: 35764792; PMCID: PMC9252919
Angiocrine polyamine production regulates adiposity
Monelli E, Villacampa P, Zabala-Letona A, Martinez-Romero A, Llena J, Beiroa D, Gouveia L, Chivite I, Zagmutt S, Gama-Perez P, Osorio-Conles O, Muixi L, Martinez-Gonzalez A, Castillo SD, MartÃn-MartÃn N, Castel P, Valcarcel-Jimenez L, Garcia-Gonzalez I, Villena JA, Fernandez-Ruiz S, Serra D, Herrero L, Benedito R, Garcia-Roves P, Vidal J, Cohen P, Nogueiras R, Claret M, Carracedo A, Graupera M
Nat Metab. 2022 Mar;4(3):327-343. doi: 10.1038/s42255-022-00544-6. Epub 2022 Mar 14. PMID: 35288722
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, MartÃn-MartÃn N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH
J Clin Invest. 2022 Apr 1;132(7):e148667. doi: 10.1172/JCI148667. Erratum in: J Clin Invest. 2022 Oct 3;132(19): PMID: 35192545; PMCID: PMC8970678
HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes
Ilegems E, Bryzgalova G, Correia J, Yesildag B, Berra E, Ruas JL, Pereira TS, Berggren PO
Sci Transl Med. 2022 Mar 30;14(638):eaba9112. doi: 10.1126/scitranslmed.aba9112. Epub 2022 Mar 30. PMID: 35353540
ChemPert: mapping between chemical perturbation and transcriptional response for non- cancer cells
Zheng M, Okawa S, Bravo M, Chen F, MartÃnez-Chantar ML, Del Sol A
Nucleic Acids Res. 2023 Jan 6;51(D1):D877-D889. doi: 10.1093/nar/gkac862. PMID: 36200827; PMCID: PMC9825489
Immobilization of Biantennary N-Glycans Leads to Branch Specific Epitope Recognition by LSECtin
Bertuzzi S, Peccati F, Serna S, Artschwager R, Notova S, Thépaut M, Jiménez- Osés G, Fieschi F, Reichardt NC, Jiménez-Barbero J, Ardá A
ACS Cent Sci. 2022 Oct 26;8(10):1415-1423. doi: 10.1021/acscentsci.2c00719. Epub 2022 Sep 20. PMID: 36313162; PMCID: PMC9615123
A glutamine-based single α-helix scaffold to target globular proteins
Escobedo A, Piccirillo J, Aranda J, Diercks T, Mateos B, Garcia-Cabau C, Sánchez-Navarro M, Topal B, Biesaga M, Staby L, Kragelund BB, GarcÃa J, Millet O, Orozco M, Coles M, Crehuet R, Salvatella X
Nat Commun. 2022 Nov 18;13(1):7073. doi: 10.1038/s41467-022-34793-6. PMID: 36400768; PMCID: PMC9674830
Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage
González-Recio I, Simón J, Goikoetxea-Usandizaga N, Serrano-Maciá M, Mercado- Gómez M, RodrÃguez-Agudo R, Lachiondo-Ortega S, Gil-Pitarch C, Fernández- RodrÃguez C, Castellana D, Latasa MU, Abecia L, Anguita J, Delgado TC, Iruzubieta P, Crespo J, Hardy S, Petrov PD, Jover R, Avila MA, MartÃn C, Schaeper U, Tremblay ML, Dear JW, Masson S, McCain MV, Reeves HL, Andrade RJ, Lucena MI, Buccella D, MartÃnez-Cruz LA, MartÃnez-Chantar ML
Nat Commun. 2022 Nov 25;13(1):6816. doi: 10.1038/s41467-022-34262-0. PMID: 36433951; PMCID: PMC9700862
CryoEM structural exploration of catalytically active enzyme pyruvate carboxylase
López-Alonso JP, Lázaro M, Gil-Cartón D, Choi PH, Dodu A, Tong L, Valle M
Nat Commun. 2022 Oct 19;13(1):6185. doi: 10.1038/s41467-022-33987-2. Erratum in: Nat Commun. 2022 Nov 16;13(1):7009. PMID: 36261450; PMCID: PMC9581989
Mechanism of cooperative N-glycan processing by the multi-modular endoglycosidase EndoE
GarcÃa-Alija M, Du JJ, Ordóñez I, Diz-Vallenilla A, Moraleda-Montoya A, Sultana N, Huynh CG, Li C, Donahue TC, Wang LX, Trastoy B, Sundberg EJ, Guerin ME
Nat Commun. 2022 Mar 3;13(1):1137. doi: 10.1038/s41467-022-28722-w. PMID: 35241669; PMCID: PMC8894350
Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis
Sáenz de Urturi D, Buqué X, Porteiro B, Folgueira C, Mora A, Delgado TC, Prieto-Fernández E, Olaizola P, Gómez-Santos B, Apodaka-Biguri M, González- Romero F, Nieva-Zuluaga A, Ruiz de Gauna M, Goikoetxea-Usandizaga N, GarcÃa-RodrÃguez JL, Gutierrez de Juan V, Aurrekoetxea I, Montalvo-Romeral V, Novoa EM, MartÃn-Guerrero I, Varela-Rey M, Bhanot S, Lee R, Banales JM, Syn WK, Sabio G, MartÃnez-Chantar ML, Nogueiras R, Aspichueta
Nat Commun. 2022 Mar 1;13(1):1096. doi: 10.1038/s41467-022-28749-z. PMID: 35232994; PMCID: PMC8888704
Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease
Barbier-Torres L, Murray B, Yang JW, Wang J, Matsuda M, Robinson A, Binek A, Fan W, Fernández-Ramos D, Lopitz-Otsoa F, Luque-Urbano M, Millet O, Mavila N, Peng H, Ramani K, Gottlieb R, Sun Z, Liangpunsakul S, Seki E, Van Eyk JE, Mato JM, Lu SC
Nat Commun. 2022 Jan 28;13(1):557. doi: 10.1038/s41467-022-28201-2. PMID: 35091576; PMCID: PMC8799735
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
MartÃnez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, MartÃn-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM
Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17. PMID: 35220605; PMCID: PMC9790568
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
Ruiz de Gauna M, Biancaniello F, González-Romero F, Rodrigues PM, Lapitz A, Gómez-Santos B, Olaizola P, Di Matteo S, Aurrekoetxea I, Labiano I, Nieva-Zuluaga A, Benito-Vicente A, Perugorria MJ, Apodaka-Biguri M, Paiva NA, Sáenz de Urturi D, Buqué X, Delgado I, MartÃn C, Azkargorta M, Elortza F, Calvisi DF, Andersen JB, Alvaro D, Cardinale V, Bujanda L, Banales JM, Aspichueta P
Hepatology. 2022 Dec;76(6):1617-1633. doi: 0.1002/hep.32344. Epub 2022 Feb 8. PMID: 35030285; PMCID: PMC979056
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma
Rackles E, Lopez PH, Falcon-Perez JM
Semin Cancer Biol. 2022 Dec;87:148-159. doi: 10.1016/j.semcancer.2022.11.004. Epub 2022 Nov 11. PMID: 36375777
Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients
Capelle CM, Ciré S, Domingues O, Ernens I, Hedin F, Fischer A, Snoeck CJ, Ammerlaan W, Konstantinou M, Grzyb K, Skupin A, Carty CL, Hilger C, Gilson G, Celebic A, Wilmes P, Del Sol A, Kaplan IM, Betsou F, Abdelrahman T, Cosma A, Vaillant M, Fagherazzi G, Ollert M, Hefeng FQ
Cell Rep Med. 2022 Mar 29;3(4):100600. doi: 10.1016/j.xcrm.2022.100600. PMID: 35480624; PMCID: PMC8960124
Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters
Wang Z, Gimeno A, Lete MG, Overkleeft HS, van der Marel GA, Chiodo F, Jiménez-Barbero J, Codée JDC
Angew Chem Int Ed Engl. 2023 Jan 2;62(1):e202211940. doi: 10.1002/anie.202211940. Epub 2022 Dec 1. PMID: 36350770; PMCID: PMC10107948
Protoglobin-Catalyzed Formation of cis-Trifluoromethyl-Substituted Cyclopropanes by Carbene Transfer
Schaus L, Das A, Knight AM, Jimenez-Osés G, Houk KN, Garcia-Borràs M, Arnold FH, Huang X
Angew Chem Int Ed Engl. 2023 Jan 23;62(4):e202208936. doi: 10.1002/anie.202208936. Epub 2022 Dec 19. PMID: 36533936; PMCID: PMC9894577
The SARS-CoV-2 Spike Glycoprotein Directly Binds Exogeneous Sialic Acids: A NMR View
Unione L, Moure MJ, Lenza MP, Oyenarte I, Ereño-Orbea J, Ardá A, Jiménez- Barbero J
Angew Chem Int Ed Engl. 2022 Apr 25;61(18):e202201432. doi:10.1002/anie.202201432. Epub 2022 Mar 7. PMID: 35191576; PMCID: PMC9074024
Platform for Orthogonal N-Cysteine-Specific Protein Modification Enabled by Cyclopropenone Reagents
Istrate A, Geeson MB, Navo CD, Sousa BB, Marques MC, Taylor RJ, Journeaux T, Oehler SR, Mortensen MR, Deery MJ, Bond AD, Corzana F, Jiménez-Osés G, Bernardes GJL
J Am Chem Soc. 2022 Jun 15;144(23):10396-10406. doi: 10.1021/jacs.2c02185. Epub 2022 Jun 5. PMID: 35658467; PMCID: PMC9490850
Introducing the Catalytic Amination of Silanes via Nitrene Insertion
RodrÃguez AM, Pérez-RuÃz J, Molina F, Poveda A, Pérez-Soto R, Maseras F, DÃaz-Requejo MM, Pérez PJ
J Am Chem Soc. 2022 Jun 15;144(23):10608-10614. doi: 10.1021/jacs.2c03739. Epub 2022 Jun 1. PMID: 35648453; PMCID: PMC9490852
Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry
Ferhati X, Jiménez-Moreno E, Hoyt EA, Salluce G, Cabeza-Cabrerizo M, Navo CD, Compañón I, Akkapeddi P, Matos MJ, Salaverri N, Garrido P, MartÃnez A, Laserna V, Murray TV, Jiménez-Osés G, Ravn P, Bernardes GJL, Corzana F
J Am Chem Soc. 2022 Mar 30;144(12):5284-5294. doi: 10.1021/jacs.1c07675. Epub 2022 Mar 16. PMID: 35293206; PMCID: PMC8972253
Ultrasmall Manganese Ferrites for In Vivo Catalase Mimicking Activity and Multimodal Bioimaging
Carregal-Romero S, Miguel-Coello AB, MartÃnez-Parra L, MartÃ-Mateo Y, Hernansanz-AgustÃn P, Fernández-Afonso Y, Plaza-GarcÃa S, Gutiérrez L, Muñoz- Hernández MDM, Carrillo-Romero J, Piñol-Cancer M, Lecante P, Blasco-Iturri Z, Fadón L, Almansa-GarcÃa AC, Möller M, Otaegui D, EnrÃquez JA, Groult H, RuÃz- Cabello J
Small. 2022 Apr;18(16):e2106570. doi: 10.1002/smll.202106570. Epub 2022 Mar 8. PMID: 35263020
Neural network learning defines glioblastoma features to be of neural crest perivascular or radial glia lineages
Hu Y, Jiang Y, Behnan J, Ribeiro MM, Kalantzi C, Zhang MD, Lou D, Häring M, Sharma N, Okawa S, Del Sol A, Adameyko I, Svensson M, Persson O, Ernfors P
Sci Adv. 2022 Jun 10;8(23):eabm6340. doi: 10.1126/sciadv.abm6340. Epub 2022 Jun 8. PMID: 35675414; PMCID: PMC9177076
A switch from α-helical to β-strand conformation during co-translational protein folding
Agirrezabala X, Samatova E, Macher M, Liutkute M, Maiti M, Gil-Carton D, Novacek J, Valle M, Rodnina MV
EMBO J. 2022 Feb 15;41(4):e109175. doi: 10.15252/embj.2021109175. Epub 2022 Jan 7. PMID: 34994471; PMCID: PMC8844987
Density and Neuronal Biomarkers in Cancer
Ali SR, Jordan M, Nagarajan P, Amit M
Cancers (Basel). 2022 Oct 1;14(19):4817. doi: 10.3390/cancers14194817. PMID: 36230740; PMCID: PMC9561962
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation
Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L, Zuniga AG, Arruabarrena-Aristorena A, Cocco E, Blawski R, Kittane S, Zhang Y, Sallaku M, Baldino L, Hristidis V, Chandarlapaty S, Abdel-Wahab O, Leslie C, Scaltriti M, Toska E
Cancer Res. 2022 Jun 15;82(12):2269-2280. doi: 10.1158/0008-5472.CAN-22-0446. PMID: 35442400; PMCID: PMC9354703
Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity
Auzmendi-Iriarte J, Otaegi-Ugartemendia M, Carrasco-Garcia E, Azkargorta M, Diaz A, Saenz-Antoñanzas A, Andermatten JA, Garcia-Puga M, Garcia I, Elua-Pinin A, Ruiz I, Sampron N, Elortza F, Cuervo AM, Matheu A
Cancer Res. 2022 Apr 1;82(7):1283-1297. doi: 10.1158/0008-5472.CAN-21-2161. PMID: 35131870; PMCID: PMC9359743
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Colyn L,. Alvarez-Sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, Vlachogiannis G, Rae C, Pineda-Lucena A, Casadei-Gardini A, Pedica F, Aldrighetti L, López-López A, López-Gonzálvez A, Barbas C, Ciordia S, Van Liempd SM, Falcón-Pérez JM, Urman J, Sangro B, Vicent S, Iraburu MJ, Prosper F, Nelson LJ, Banales JM, Martinez-Chantar ML, Marin JJG, Braconi C, Trautwein C, Corrales FJ, Cubero FJ, Berasain C, Fernandez-Barrena MG, Avila MA
J Exp Clin Cancer Res. 2022 May 26;41(1):183. doi: 10.1186/s13046-022-02386-2. PMID: 35619118; PMCID: PMC9134609
Reviews
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies
Camilleri M, Zhernakova A, Bozzarelli I, D'Amato M. Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies
Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):689-702. doi: 10.1038/s41575-022-00662-2. Epub 2022 Aug 10. PMID: 35948782
HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models
Assoni G, La Pietra V, Digilio R, Ciani C, Licata NV, Micaelli M, Facen E, Tomaszewska W, Cerofolini L, Pérez-Rà fols A, Varela Rey M, Fragai M, Woodhoo A, Marinelli L, Arosio D, Bonomo I, Provenzani A, Seneci P
Adv Drug Deliv Rev. 2022 Feb;181:114088. doi: 10.1016/j.addr.2021.114088. Epub 2021 Dec 20. PMID: 34942276
Editorial Activity
-
-
JoaquÃn Castilla
Advisory BoardJuan Anguita
Editor Board
-
-
Óscar Millet
Associate Editor
-
-
Óscar Millet
Editor Board
-
-
Juan Anguita
Editor Board
-
-
Malu MartÃnez Chantar
Editor Board
-
-
Óscar Millet
Editor Board
-
-
Rosa Barrio
Editor BoardJuan Anguita
Senior EditorÓscar Millet
Editor Board
-
-
Félix Elortza
Editor Board
-
-
Malu MartÃnez Chantar
Associate Editor
-
-
AsÃs Palazón
Associate EditorJuan Anguita
Guest Associate Editor
-
-
JoaquÃn Castilla
Associate Editor
-
-
Rosa Barrio
Associate Editor
-
-
MarÃa Vivanco
Editor Board
-
-
Arkaitz Carracedo
Consultant Editor
-
-
Jesús Jiménez-Barbero
Associate Editor
-
-
Jesús Jiménez-Barbero
Advisory Board
-
-
Malu MartÃnez Chantar
Editor Board
-
-
Antonio Del Sol
Editor BoardÓscar Millet
Editor Board
-
-
Félix Elortza
Editor Board
-
-
Rosa Barrio
Guest Editor
Edurne Berra
Associate Editor
Juan Manuel Falcón
Deputy Editor
Jesús Jiménez-Barbero
Advisory Board
Jesús Jiménez-Barbero
Advisory Board
Robert Kypta
Editor Board
Jesús Jiménez-Barbero
Editor Board
Óscar Millet
Editor Board
JoaquÃn Castilla
Editor Board
JoaquÃn Castilla
Editor Board
Juan Anguita
Editor Board
PhD Thesis
0 in progress
Collaboration RVCTI
 |
 |
 |
|
 |
 |
 |
|
 |
 |
 |
|
0 RVCTI
(Basque Network)
Theses
Carmen Fernández RodrÃguez
Novel surface engineering approaches for protein crystallization and structural insights into the enzimes of reverse transsulfuration from the human pathogens Toxoplasma gondii and Pseudomonas aeruginosa.
Guillermo GarcÃa Marquina
Acyltransferase LovD as a Simvastatin synthase
Ariane Schaub Clerigué
PGC-driven transcriptional control of the cell secretome in prostate cancer: molecular and biological analysis
Javier Plou Izquierdo
Label-free monitoring of tumor models by surface-enhanced raman scattering
Pilar Castellnou Arenas
Synthesis of positron emitter-labelled amino acids: Application to the investigation of metabolic preferences and vulnerabilities in a mouse prostate cancer model
Naroa Goikoetxea-Usandizaga
Role of mitochondria in liver diseases
Miguel Tamayo Caro
Neddylation in schwann cell myelination
Jon Imanol Quintana GarcÃa
NMR and molecular recognition: The interaction of human galectin-4 with the histo blood group antigens and with pathogen-associated molecules
Nicanor Zalba Olaizola
On the effect of cosolutes and crowders in the stability and kinetic properties of proteins
Irene González Recio
Unveiling magnesioum homeostasis in liver diseases
Julia San Millán Gutiérrez
Analysis of the essentialy of phosphatidylserine decarboxylase in endocrine resistant breast cancer cells
Carlos Miguel DÃaz DomÃnguez
Estudio de la diversidad de variantes de las proteinas del prion de cérvidos, su capaciidad de malplegamiento en influencia sobre la emergencia de cepas con caracterÃsticas distintivas
Orhi Barroso Gomila
Development of biotin-based strategies to dissect the ubiquitin code
Sara Bertuzzi
Lectin-Glycan Interactions: new NMR insights on the role of dynamics and presentation by using state-of-the-art NMR methodologies
Jone Ibáñez Pérez
Free and extracellular vesicle-associated micro RNAs from endometrial fluid as non-invasive diagnostic biomarkers of implantative endometrium
Gabriel Soares Guerra
Vaccine and structural studies of Schmallenberg virus
Training – Doctoral Candidates
The CIC bioGUNE Advanced Training Program
Introduction to CIC bioGUNE RESEARCH for new PhD Candidates
October 2022
New Group Leader
Starting in January 2023
Raúl Pérez-Jiménez
Ikerbasque Professor
Synthetic Biology
2013
PhD - 2005
Dissemination: Press
Radio & TV
International Visibility
Organization of symposia
CIC bioGUNE
- 115 asistentes
- 60% internacional
- 53% mujeres
Palacio Euskalduna - Bilbao
- 179 asistentes
- 70% internacional
- 38% mujeres
Palacio Euskalduna - Bilbao
- 200 asistentes
- 70% internacional
- 50% mujeres
Financiación Bilbao Ekintza
Virtual
- 301 asistentes
- 87% internacional
Palacio Euskalduna - Bilbao
- 275 asistentes
- 77% internacional
- 61% mujeres
Confirmed 2024 & 2026
Virtual
- 900 people
Palacio Euskalduna - Bilbao
- 1000 people
- 400 posters
Outreach
Carrera solidaria contra el cáncer de mama
Carrera solidaria "Raras pero no invisibles"
April 29
Marcha contra el Cáncer (Vitoria)
October 9
Entrega de cuentos didácticos infantiles
II Curso OMICAS en el estudio de las enfermedades hepáticas y digestivas
October 5-6
Cuestación Anual AECC
May 12
